Immunitor is a commercial stage private company, originally founded in 2001 in Thailand, then incorporated in the USA, Canada, Russia, Mongolia and China. Company has over 12 products in pipeline that are produced at GMP-complying facility. Company has developed unique proprietary platform, which allows to formulate as a simple pill a wide range of biologics from recombinant or natural source. The technology is protected by an extensive global patent portfolio. As a global pioneer in orally delivered immunotherapies or therapeutic vaccines, Immunitor specializes in the treatment of bacterial and fungal infections, tuberculosis, AIDS, hepatitis, influenza, atherosclerosis, hypertension, diabetes, obesity, kidney failure, allergy and autoimmunity, neurodegenerative diseases, and cancer. Immunitor has conducted multiple clinical trials and has a compelling valuation. Leading products in Phase III stage are Hepko-V5 for advanced liver cancer or hepatocellular carcinoma (HCC); V6 for treatment of metabolic diseases, i.e., atherosclerosis, hypertension, obesity and diabetes; and V7 for treating tuberculosis. Additional clinical trials are planned in US and China to obtain marketing license in these countries.